Detection of Unusual Peritoneal Metastases of Prostate Cancer With 68Ga–Prostate-Specific Membrane Antigen PET/CT

Peritoneal metastasis of prostate cancer (PC) is unusual site of metastatic disease; only limited case reports are published in literature. Ga-68-prostate-specific membrane antigen (PSMA) PET/CT is recently used for detection of PC metastasis with high accuracy rates. We present a case of a 68-year-old man with disseminated peritoneal metastases and abdominal metastatic lymph nodes of PC, demonstrated in Ga-68-PSMA PET/CT with intense PSMA uptake

Detection of Unusual Peritoneal Metastases of Prostate Cancer With Ga-68-Prostate-Specific Membrane Antigen PET/CT

Peritoneal metastasis of prostate cancer (PC) is unusual site of metastatic disease; only limited case reports are published in literature. Ga-68-prostate-specific membrane antigen (PSMA) PET/CT is recently used for detection of PC metastasis with high accuracy rates. We present a case of a 68-year-old man with disseminated peritoneal metastases and abdominal metastatic lymph nodes of PC, demonstrated in Ga-68-PSMA PET/CT with intense PSMA uptake

Ga-68-PSMA PET/CT and PET/MRI in high-risk prostate cancer patients

Treatment of high-risk prostate cancer (HRPCa) is challenging. Local staging and metastatic evaluation are important for the patient management. Recently, prostate-specific membrane antigen (PSMA)-based imaging modalities such as PSMA PET/CT and PET/MRI have received significant attention for detection of recurrent prostate cancer sites with elevated prostate-specific antigen levels, after therapy. Current evidence suggests that these imaging modalities may also have a role for the management of patients with HRPCa. In this review, we discuss PSMA-based imaging modalities in the management of patients with HRPCa

Prosthodontic treatment of a patient with hemimandibular elongation: A clinical report

This clinical report describes prosthodontic treatment of a patient with hemimandibular elongation that resulted in significant dentofacial asymmetry. A maxillary metal-ceramic fixed dental prosthesis and crowns were fabricated. To eliminate the negative horizontal overlap, 3 mandibular teeth were reduced to the gingival level. The mandibular prosthetic restoration was completed with metal and composite resin using an electroforming technique

Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management.

Fibroblast activation protein (FAP), overexpressed on cancer-associated fibroblasts (CAFs), is a novel target for molecular imaging of various tumors. Recently, the development of several small-molecule FAP inhibitors for radiolabeling with (68)Ga has resulted in the emergence of studies evaluating its clinical role in cancer imaging. Preliminary findings have demonstrated that, in contrast to radiotracers taking advantage of cancer-specific targets such as PSMA and DOTATATE, FAPs as a target are the most promising that can compete with (18)FDG in terms of widespread indications. They also have the potential to overcome the shortcomings of (18)FDG, particularly false-positive uptake due to inflammatory or infectious processes, low sensitivity in certain cancer types, and radiotherapy planning. In addition, the attractive theranostic properties may facilitate the treatment of many refractory cancers. This review summarizes the current FAP variants and related clinical studies, focusing on radiopharmacy, dosimetry, and diagnostic and theranostic applications